

Selection by Prediction

Prediction-assisted screening and discovery with conformal p-values

Ying Jin

Department of Statistics
Stanford University

[Joint work with Emmanuel Candès](#)



One World Seminar on Mathematics of Machine Learning, April 19, 2023

ML prediction assists decision

HIRING RESOURCES | 9 MIN READ

How Good Machine Learning in Recruitment Can Radically Transform Your Hiring

[VerVoe.com]

The Impact of Machine Learning on Modern Recruitment

 SmartDreamers Team • Social Recruiting, Automation Oct 18 • 4 min read

[smartdreamers.com]

Market Insights — 24 min read

Machine learning in recruitment: a deep dive

Machine Learning's promise is to find the perfect candidate and assess them without your interference, but what is it exactly and how does it really help you?

[HeroHunt.ai]

Job hiring: Who to reach out to?
Who to proceed to interview?

ML prediction assists discovery

Deep Learning

Shortcuts to Simulation: How Deep Learning Accelerates Virtual Screening for Drug Discovery

May 11, 2020 ⌚ 14 min read

[DZone.com]

Automating Drug Discovery With Machine Learning


Article Published: April 16, 2021 | [Neeta Ratanghayra, MPharm](#)

[technologynetworks.com]


Drug discovery: Which molecules/compounds to proceed to physical screening and clinical trials?

Decision and discovery processes

- ▶ Find a few interesting cases from a huge pool




Disease (COVID)



Candidate drugs




Position



Job applicants


Decision and discovery processes

- ▶ Find a few interesting cases from a huge pool




Decision and discovery processes

- ▶ Find a few interesting cases from a huge pool




Decision and discovery processes

- ▶ Find a few interesting cases from a huge pool




The role of ML in decision and discovery processes

- ▶ Find a few interesting cases from a huge pool




The role of ML in decision and discovery processes

- ▶ Error on the selected is concerning because of costly follow-up studies



This work

- ▶ Screening with error control on the selected candidates



Mathematical setup

- ▶ Any pre-trained ML model $\hat{\mu}: \mathcal{X} \rightarrow \mathcal{Y}$
- ▶ Training data $\{(X_i, Y_i)\}_{i=1}^n$ (already-screened drugs)
- ▶ Test samples $\{(X_{n+j}, Y_{n+j})\}_{j=1}^m$, only observe covariates $\{X_{n+j}\}_{j=1}^m$ (new drugs)
- ▶ For now: assume training and test samples are **i.i.d.** from an unknown distribution
 - ▶ Drugs drawn from a diverse drug library
 - ▶ Will be relaxed later on to allow for distribution shift
- ▶ Interested in large outcomes: $Y_{n+j} > c_{n+j}$ for some user-specified thresholds c_{n+j}

Guarantees we seek for

- ▶ Recall: Interested in large outcomes: $Y_{n+j} > c_{n+j}$ for some user-specified c_{n+j}
- ▶ Our goal is to find a subset $\mathcal{R} \subseteq \{1, \dots, m\}$ as “promising candidates”
- ▶ While controlling the false discovery rate (FDR) below some $q \in (0, 1)$

$$FDR = \mathbb{E}[FDP], \quad FDP = \frac{\sum_{j=1}^m \mathbf{1}\{j \in \mathcal{R}, Y_{n+j} \leq c_{n+j}\}}{1 \vee |\mathcal{R}|}$$

[Benjamini and Hochberg, 1995]

Number of selected but uninteresting units

\approx Number of selected units

- ▶ FDR measures the **proportion** of follow-up resources wasted on uninteresting cases

Reliable prediction: conformal inference

- ▶ Conformal prediction for reliable predictive inference [Vovk et al., 2005]

- ▶ Build any score function $V(x, y)$ based on the ML model, such as $V(x, y) = -|y - \hat{\mu}(x)|$
- ▶ Compute $V_i = V(X_i, Y_i)$ for $i = 1, 2, \dots, n$
- ▶ Construct prediction interval

$$\hat{C}(X_{n+j}; \alpha) = \{y: V(X_{n+j}, y) \geq \text{Quantile}(\alpha, \hat{P}_n(V_1, \dots, V_n))\}$$

- ▶ Assumption-free guarantee:


$$\mathbb{P}(Y_{n+j} \in \hat{C}(X_{n+j}; \alpha)) \geq 1 - \alpha, \quad \forall j = 1, \dots, m$$

- ▶ True for any score function $V(x, y)$ that builds on any (independently trained) ML model

- ▶ A literature on using conformal prediction intervals for drug discovery [Norinder et al., 2014, Svensson et al., 2017, Ahlberg et al., 2017, Svensson et al., 2018, Cortes-Ciriano and Bender, 2019, Wang et al., 2022]

Validity for one single point is not sufficient


- ▶ $\mathbb{P}(Y_{n+j} \in \hat{C}(X_{n+j}; \alpha)) \geq 1 - \alpha$ over the randomness in training data and the j -th test data
- ▶ In binary classification, to find $Y_{n+j} = 1$ with $\leq q$ error, choose $\hat{C}(X_{n+j}, q) = \{1\}$?
 - ▶ Valid if those $\hat{C}(X_{n+j}, q) = \{1\}$ covers Y_{n+j} with probability $1 - q$
 - ▶ Coverage on average does not imply coverage on selected



- ▶ Constructing prediction intervals and then selecting promising ones is the approach in most works regarding conformal inference for drug discovery

Validity for one single point is not sufficient

- ▶ $\mathbb{P}(Y_{n+j} \in \hat{C}(X_{n+j}; \alpha)) \geq 1 - \alpha$ over the randomness in training data and the j -th test data
- ▶ In binary classification, to find $Y_{n+j} = 1$ with $\leq q$ error, choose $\hat{C}(X_{n+j}, q) = \{1\}$?
 - ▶ Valid if those $\hat{C}(X_{n+j}, q) = \{1\}$ covers Y_{n+j} with probability $1 - q$
 - ▶ Coverage on average does not imply coverage on selected



Build $(1 - \alpha)$ prediction sets taking the form $\{0\}, \{1\}, \{0,1\}$
Select those $\hat{C}(X_{n+j}; \alpha) = \{1\}$ to get the **orange** curve
Marginal miscoverage for the **dark** curve

Our approach: thresholding confidence measure


- ▶ Recall: Interested in large outcomes: $Y_{n+j} > c_{n+j}$ for some user-specified c_{n+j}
- ▶ Main idea: use a sequence of prediction intervals to decide a **confidence measure**, then leverage multiple testing ideas to threshold the confidence measure
 - ▶ Build any **monotone** score function $V(x, y)$, i.e., $y \leq y'$ implies $V(x, y) \leq V(x, y')$
 - ▶ One-sided residual $V(x, y) = y - \hat{\mu}(x)$
 - ▶ Fitted cumulative distribution function $V(x, y) = \hat{\mathbb{P}}(Y \leq y \mid X = x)$
 - ▶ Compute $V_i = V(X_i, Y_i)$ for $i = 1, 2, \dots, n$
 - ▶ Compute test scores $\hat{V}_{n+j} = V(X_{n+j}, c_{n+j})$ for $j = 1, 2, \dots, m$
 - ▶ Compute confidence measures (p-value in statistics) \approx rank of \hat{V}_{n+j} among training scores $\{V_i\}_{i=1}^n$

$$p_j = \frac{\sum_{i=1}^n \mathbf{1}\{V_i < \hat{V}_{n+j}\} + U_j}{n + 1}, \quad U_j \sim \text{Unif}[0, 1]$$

- ▶ Get selection set \mathcal{R} by **Benjamini-Hochberg procedure** applied to $\{p_j\}$ at **level q**

Our approach: thresholding confidence measure

- ▶ Back to the implied pipeline in drug discovery



Interpreting the confidence measure

- ▶ Recall: Interested in large outcomes: $Y_{n+j} > c_{n+j}$ for some user-specified c_{n+j}


$$p_j = \frac{\sum_{i=1}^n \mathbf{1}\{V_i < \hat{V}_{n+j}\} + U_j}{n+1}, \quad U_j \sim \text{Unif}[0,1]$$

$$p_j \approx \inf \{ \alpha : c_{n+j} \notin \hat{C}(X_{n+j}; \alpha) \}$$

$$\hat{C}(X_{n+j}; \alpha) = \{y : V(X_{n+j}, y) \geq \text{Quantile}(\alpha, \hat{P}_n(V_1, \dots, V_n))\}$$

\approx critical point α such that $\hat{C}(X_{n+j}; \alpha)$ is all larger than c_{n+j}

A smaller p_j means c_{n+j} is smaller than the typical behavior of Y_{n+j}



By monotonicity,
 $\hat{C}(X_{n+j}; \alpha) = [\eta(X_{n+j}; \alpha), \infty)$

A bit more statistics

- ▶ Recall: Interested in large outcomes: $Y_{n+j} > c_{n+j}$ for some user-specified c_{n+j}
- ▶ This can be viewed as testing the **random** null hypotheses

$$H_j: Y_{n+j} \leq c_{n+j}$$

- ▶ Our confidence measure p_j is a valid p-value for testing H_j

$$\mathbb{P}(p_j \leq t, H_j \text{ is true}) \leq t, \quad \forall t \in [0,1]$$

Valid type-I control that accounts for the randomness in H_j

FDR control with the confidence measure

- ▶ Get selection set \mathcal{R} by **Benjamini-Hochberg procedure** applied to $\{p_j\}$ at **level q**
 - ▶ Set $\mathcal{R} = \{j: p_j \leq q\hat{k}/m\}$, where $\hat{k} = \max \left\{ k: \sum_{j=1}^m \mathbf{1}\{p_j \leq qk/m\} \geq k \right\}$

Theorem (J. and Candès, 2022)

If $V(x, y)$ is monotone, the training and test data are i.i.d., and for each j , data in $\{Z_i\}_{i=1}^n \cup \{\tilde{Z}_{n+\ell}\}_{\ell \neq j} \cup \{Z_{n+j}\}$ are mutually independent for $Z_i = (X_i, Y_i)$ and $\tilde{Z}_{n+j} = (X_{n+j}, c_{n+j})$. Then for any $q \in (0, 1)$, the output \mathcal{R} at level q obeys **$FDR \leq q$** .

- ▶ True for random c_{n+j} (will my health risk tomorrow be higher than today?)

A bit more math

- ▶ This is a new statistical problem: random p-values for random hypotheses
- ▶ Also, p-values are mutually dependent, which is typically challenging for FDR control
- ▶ **Why it works:** the p_j are “positively dependent”, which ensures FDR control

- ▶ Proof step 1: **Leave-one-out**

$$FDR \leq \sum_{j=1}^m \mathbb{E} \left[\frac{\mathbf{1}\{j \in \mathcal{R}_{j \rightarrow *}\}}{1 \vee |\mathcal{R}_{j \rightarrow *}|} \right]$$

- ▶ Proof step 2: **Uniform distribution + positive dependence**

$$\mathbb{E} \left[\frac{\mathbf{1}\{j \in \mathcal{R}_{j \rightarrow *}\}}{1 \vee |\mathcal{R}_{j \rightarrow *}|} \right] \leq \frac{q}{m}$$

A bit more math

- ▶ Proof step 1: **Leave-one-out**

- ▶ Define $p_j^* = \frac{\sum_{i=1}^n \mathbf{1}\{V_i < V_{n+j}\} + U_j}{n+1}$ with the “true test score” $V_{n+j} = V(X_{n+j}, Y_{n+j})$ (uncomputable, just for analysis)
- ▶ Let $\mathcal{R}_{j \rightarrow *}$ be the rejection set of BH applied to $p_j^* \cup \{p_\ell\}_{\ell \neq j}$ at level q
- ▶ Because of monotonicity, one can show that $\mathcal{R} = \mathcal{R}_{j \rightarrow *}$ on the event $\{Y_{n+j} \leq c_{n+j} \text{ and } j \in \mathcal{R}\}$
- ▶ This implies

$$FDR = \sum_{j=1}^m \mathbb{E} \left[\frac{\mathbf{1}\{j \in \mathcal{R}, Y_{n+j} \leq c_{n+j}\}}{1 \vee |\mathcal{R}|} \right] \leq \sum_{j=1}^m \mathbb{E} \left[\frac{\mathbf{1}\{j \in \mathcal{R}_{j \rightarrow *}, Y_{n+j} \leq c_{n+j}\}}{1 \vee |\mathcal{R}_{j \rightarrow *}|} \right] \leq \sum_{j=1}^m \mathbb{E} \left[\frac{\mathbf{1}\{j \in \mathcal{R}_{j \rightarrow *}\}}{1 \vee |\mathcal{R}_{j \rightarrow *}|} \right]$$

A bit more math

- ▶ Proof step 1: **Leave-one-out**

$$FDR \leq \sum_{j=1}^m \mathbb{E} \left[\frac{\mathbf{1}\{j \in \mathcal{R}_{j \rightarrow *}\}}{1 \vee |\mathcal{R}_{j \rightarrow *}|} \right]$$

- ▶ Proof step 2: **Uniform distribution + positive dependence**

- ▶ For i.i.d. data, the oracle p-value is uniformly distributed $p_j^* \sim \text{Unif}[0,1]$
- ▶ Also, $\{p_\ell\}_{\ell \neq j}$ are **PRDS** on p_j^*
- ▶ This implies for every j , [Benjamini and Yekutieli, 2001]

$$\mathbb{E} \left[\frac{\mathbf{1}\{j \in \mathcal{R}_{j \rightarrow *}\}}{1 \vee |\mathcal{R}_{j \rightarrow *}|} \right] \leq \frac{q}{m}$$

A random vector $X = (X_1, \dots, X_m)$ is **PRDS** on x_i if for any increasing set D , the probability $\mathbb{P}(X \in D \mid X_i = x)$ is increasing in x

A set D is **increasing** if $a \in D$ and $b \geq a$ implies $b \in D$

A bit more math

- ▶ This is a new statistical problem: random p-values for random hypotheses
- ▶ Also, p-values are mutually dependent, which is typically challenging for FDR control
- ▶ **Why it works:** the p_j are “positively dependent”, which ensures FDR control

- ▶ Proof step 1: **Leave-one-out**

$$FDR \leq \sum_{j=1}^m \mathbb{E} \left[\frac{\mathbf{1}\{j \in \mathcal{R}_{j \rightarrow *}\}}{1 \vee |\mathcal{R}_{j \rightarrow *}|} \right]$$

Takeaway:

- ▶ p_j controls the false selection error for each test sample j
- ▶ p_j 's are PRDS so they work well together

- ▶ Proof step 2: **Uniform distribution + positive dependence**

$$\mathbb{E} \left[\frac{\mathbf{1}\{j \in \mathcal{R}_{j \rightarrow *}\}}{1 \vee |\mathcal{R}_{j \rightarrow *}|} \right] \leq \frac{q}{m}$$

Power boosting

- ▶ While FDR is controlled for any monotone score $V(x, y)$, some makes it powerful
- ▶ If the thresholds are constant $c_{n+j} \equiv c$, a particularly powerful choice is 'clipped' score

$$V(x, y) = +\infty \cdot \mathbf{1}\{y > c\} + c \cdot \mathbf{1}\{y \leq c\} - \hat{\mu}(x)$$

- ▶ In binary case and $c = 0$, the ideal score is monotone in $\mathbb{P}(Y = 1 \mid X = x)$ (see paper)


Real application: drug property prediction for HIV

- ▶ Binary $Y \in \{0,1\}$: whether the drug interacts with the disease
- ▶ The drug library is $n_{tot} = 41127$ in total, use 6 : 2 : 2 split
- ▶ Very sparse data: only 3% drugs are active
- ▶ Our hope: find a smaller subset to proceed so that $(1 - q)$ of the subset are active drugs
- ▶ FDR level $q \in \{0.1,0.2,0.5\}$, use a small neural network (can be more complicated)

	Realized FDR			Power			$ \mathcal{R} $		
FDR level	0.1	0.2	0.5	0.1	0.2	0.5	0.1	0.2	0.5
Powerful score	0.0957	0.196	0.495	0.0788	0.174	0.410	26.5	64.2	240
Score $V(x, y) = y - \hat{\mu}(x)$	0.0989	0.196	0.494	0.0766	0.174	0.410	25.8	64.4	239

Real application: drug-target-interaction prediction

- ▶ Davis dataset, $Y \in \mathbb{R}$ continuous binding affinities, X feature for a drug-target pair
- ▶ The drug library is $n_{tot} = 30060$ in total, use 2 : 2 : 6 split
- ▶ Set c_{n+j} as the q_{pop} -th quantile of the outcomes in the first training fold with the same binding target as test sample j , where $q_{pop} \in \{0.7, 0.8, 0.9\}$
- ▶ FDR level $q \in \{0.1, 0.2, 0.5\}$




So far, and next


- ▶ A method that turns any prediction model into a reliable selection procedure
- ▶ Theoretically, FDR control due to monotonicity and positive dependence (PRDS)
- ▶ Works reasonably well in real drug discovery tasks
 - ▶ + job hiring tasks in paper
 - ▶ + more benchmarks and applications in ongoing work
- ▶ **Next: dealing with distribution shifts**

Distribution shifts

- ▶ The only assumption for this method to work is **i.i.d.** data
- ▶ Are my evaluated drugs comparable to the unknown drugs?
 - ▶ **Yes** if the evaluated ones are drawn without preference from your library



Training drugs




New drugs


Distribution shifts

- ▶ The only assumption for this method to work is **i.i.d.** data
- ▶ Are my evaluated drugs comparable to the unknown drugs?

- ▶ **Yes** if the evaluated ones are drawn without preference from your library
- ▶ **No** if you preferred drugs with some specific structures, etc



Training drugs



New drugs

- ▶ Similar issues happen in job hiring, health monitoring, counterfactual inference...
 - ▶ Candidates documented last year may differ from current
 - ▶ Patients may differ in demographics across hospitals
 - ▶ People under treatment may be different than those under control

Extending the setting to covariate shifts

- ▶ Formally, we assume the test data are i.i.d. from some unknown \mathbb{Q}
- ▶ And the training data are i.i.d. from some unknown \mathbb{P}
- ▶ We only know that they are related by a covariate shift:
[Tibshirani et al., 2019]


$$\frac{d\mathbb{Q}}{d\mathbb{P}}(x, y) = w(x)$$

- ▶ The distribution shift is **fully attributed to covariates**


Confidence measure under covariate shift

- Under covariate shift, we need a new confidence measure

If use previous confidence measures (p-values) when there is covariate shift



p-values are no longer valid



FDR can be violated

Confidence measure under covariate shift

- ▶ Under covariate shift, we need a new confidence measure
 - ▶ Build any **monotone** score function $V(x, y)$, i.e., $y \leq y'$ implies $V(x, y) \leq V(x, y')$
 - ▶ One-sided residual $V(x, y) = y - \hat{\mu}(x)$
 - ▶ Fitted cumulative distribution function $V(x, y) = \hat{\mathbb{P}}(Y \leq y \mid X = x)$
 - ▶ Compute $V_i = V(X_i, Y_i)$ for $i = 1, 2, \dots, n$
 - ▶ Compute test scores $\hat{V}_{n+j} = V(X_{n+j}, c_{n+j})$ for $j = 1, 2, \dots, m$
 - ▶ Compute **weighted** confidence measures (p-value in statistics)

$$p_j = \frac{\sum_{i=1}^n w(X_i) \mathbf{1}\{V_i < \hat{V}_{n+j}\} + w(X_{n+j})}{\sum_{i=1}^n w(X_i) + w(X_{n+j})}$$

\approx weighted rank of \hat{V}_{n+j} among training scores $\{V_i\}_{i=1}^n$

Statistical properties

- ▶ The new confidence measure has similar statistical properties as before
- ▶ Still, we are testing the **random** null hypotheses

$$H_j: Y_{n+j} \leq c_{n+j}$$

- ▶ Our p_j is a valid p-value for testing H_j **under covariate shift**

$$\mathbb{P}(p_j \leq t, H_j \text{ is true}) \leq t, \quad \forall t \in [0,1]$$

Probability over both training
data and the test sample j

[Asserting $Y_{n+j} > c_{n+j}$ if $p_j \leq \alpha$] controls type-I error for a single test point

Statistical properties

- ▶ The new confidence measure has similar statistical properties as before
- ▶ Still, we are testing the **random** null hypotheses

$$H_j: Y_{n+j} \leq c_{n+j}$$

- ▶ Our p_j is a valid p-value for testing H_j **under covariate shift**

$$\mathbb{P}(p_j \leq t, H_j \text{ is true}) \leq t, \quad \forall t \in [0,1]$$

Probability over both training
data and the test sample j

[Asserting Y_{n+j}

point

- ▶ Does the previous recipe work?

(Recall for i.i.d.) **Takeaway:**

- ▶ p_j controls the false selection error for each test sample j
- ▶ p_j 's are PRDS so they work well together

Statistical properties

- ▶ Weighted conformal p-values are **not PRDS**

Theorem (J. and Candès, in preparation, 2023+)

Suppose we construct p_j assuming $Y_{n+j} = c_{n+j}$. Then there exists a weight function $w(\cdot)$, a monotone score function $V(\cdot, \cdot)$, such that for training and test samples obeying a covariate shift, the p-values

(Recall for i.i.d.) **Takeaway:**

- ▶ p_j controls the false selection error for each test sample j
- ▶ p_j 's are ~~PRDS~~ so they work well together

- ▶ Does the previous recipe work?


- ▶ Not sure theoretically, but works in our numerical experiments
- ▶ In forthcoming paper: A new procedure **exactly** controlling FDR in **finite** samples

Other applications of this framework


- ▶ Detecting positive individual treatment effects
 - ▶ Individual treatment effects are random variables that describe the difference in outcomes with treatment $O(1)$ versus without treatment $O(0)$
 - ▶ We are interested in whether $O_{n+j}(1) > O_{n+j}(0)$ or not
 - ▶ Equivalent to taking $Y_{n+j} = O_{n+j}(1)$ and $c_{n+j} = O_{n+j}(0)$ for a control unit
- ▶ Detecting outliers and concept drifts
 - ▶ Given a set of normal transactions from \mathbb{P} and a set of new transactions
 - ▶ We are interested in whether the new transactions are from \mathbb{Q} (covariate shift from \mathbb{P})

Summary


- ▶ In prediction-assisted screening problems, **FDR** can be a sensible measure
- ▶ A method that turns **any** prediction model into a reliable selection procedure
 - ▶ Useful if interested in “large” outcomes
 - ▶ Builds confidence scores (p-values) upon any prediction model
 - ▶ Controls FDR so that your follow-up investigations are well-deserved
- ▶ Extension to situations with covariate shifts
 - ▶ Some more complicated methodology & theory



arXiv: 2210.01408



Candidate drugs



Small set with
(1-q) true discovery